Single User License
INR 168550
Site License
INR 337100
Corporate User License
INR 505650

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Multiple Sclerosis-Pipeline Review, H1 2015

Multiple Sclerosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Multiple Sclerosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Multiple Sclerosis-Pipeline Review, H1 2015', provides an overview of the Multiple Sclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 9

Multiple Sclerosis Overview 10

Therapeutics Development 11

Multiple Sclerosis-Therapeutics under Development by Companies 13

Multiple Sclerosis-Therapeutics under Investigation by Universities/Institutes 29

Multiple Sclerosis-Pipeline Products Glance 33

Multiple Sclerosis-Products under Development by Companies 37

Multiple Sclerosis-Products under Investigation by Universities/Institutes 55

Multiple Sclerosis-Companies Involved in Therapeutics Development 59

Multiple Sclerosis-Therapeutics Assessment 222

Drug Profiles 250

Multiple Sclerosis-Recent Pipeline Updates 651

Multiple Sclerosis-Dormant Projects 781

Multiple Sclerosis-Discontinued Products 799

Multiple Sclerosis-Product Development Milestones 804

Appendix 811

List of Tables

Number of Products under Development for Multiple Sclerosis, H1 2015 44

Number of Products under Development for Multiple Sclerosis-Comparative Analysis, H1 2015 45

Number of Products under Development by Companies, H1 2015 47

Number of Products under Development by Companies, H1 2015 (Contd..1) 48

Number of Products under Development by Companies, H1 2015 (Contd..2) 49

Number of Products under Development by Companies, H1 2015 (Contd..3) 50

Number of Products under Development by Companies, H1 2015 (Contd..4) 51

Number of Products under Development by Companies, H1 2015 (Contd..5) 52

Number of Products under Development by Companies, H1 2015 (Contd..6) 53

Number of Products under Development by Companies, H1 2015 (Contd..7) 54

Number of Products under Development by Companies, H1 2015 (Contd..8) 55

Number of Products under Development by Companies, H1 2015 (Contd..9) 56

Number of Products under Development by Companies, H1 2015 (Contd..10) 57

Number of Products under Development by Companies, H1 2015 (Contd..11) 58

Number of Products under Development by Companies, H1 2015 (Contd..12) 59

Number of Products under Development by Companies, H1 2015 (Contd..13) 60

Number of Products under Development by Companies, H1 2015 (Contd..14) 61

Number of Products under Investigation by Universities/Institutes, H1 2015 63

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 64

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 65

Comparative Analysis by Late Stage Development, H1 2015 66

Comparative Analysis by Clinical Stage Development, H1 2015 67

Comparative Analysis by Early Stage Development, H1 2015 68

Comparative Analysis by Unknown Stage Development, H1 2015 69

Products under Development by Companies, H1 2015 70

Products under Development by Companies, H1 2015 (Contd..1) 71

Products under Development by Companies, H1 2015 (Contd..2) 72

Products under Development by Companies, H1 2015 (Contd..3) 73

Products under Development by Companies, H1 2015 (Contd..4) 74

Products under Development by Companies, H1 2015 (Contd..5) 75

Products under Development by Companies, H1 2015 (Contd..6) 76

Products under Development by Companies, H1 2015 (Contd..7) 77

Products under Development by Companies, H1 2015 (Contd..8) 78

Products under Development by Companies, H1 2015 (Contd..9) 79

Products under Development by Companies, H1 2015 (Contd..10) 80

Products under Development by Companies, H1 2015 (Contd..11) 81

Products under Development by Companies, H1 2015 (Contd..12) 82

Products under Development by Companies, H1 2015 (Contd..13) 83

Products under Development by Companies, H1 2015 (Contd..14) 84

Products under Development by Companies, H1 2015 (Contd..15) 85

Products under Development by Companies, H1 2015 (Contd..16) 86

Products under Development by Companies, H1 2015 (Contd..17) 87

Products under Investigation by Universities/Institutes, H1 2015 88

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 89

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 90

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 91

Multiple Sclerosis-Pipeline by 4SC AG, H1 2015 92

Multiple Sclerosis-Pipeline by AB Science, H1 2015 93

Multiple Sclerosis-Pipeline by AbbVie Inc., H1 2015 94

Multiple Sclerosis-Pipeline by Acadia Pharmaceuticals Inc., H1 2015 95

Multiple Sclerosis-Pipeline by Acorda Therapeutics, Inc., H1 2015 96

Multiple Sclerosis-Pipeline by Actelion Ltd, H1 2015 97

Multiple Sclerosis-Pipeline by Addex Therapeutics Ltd, H1 2015 98

Multiple Sclerosis-Pipeline by Aegis Therapeutics, LLC, H1 2015 99

Multiple Sclerosis-Pipeline by Affectis Pharmaceuticals AG, H1 2015 100

Multiple Sclerosis-Pipeline by AiCuris GmbH & Co. KG, H1 2015 101

Multiple Sclerosis-Pipeline by Alkermes Plc, H1 2015 102

Multiple Sclerosis-Pipeline by Allozyne, Inc., H1 2015 103

Multiple Sclerosis-Pipeline by Amarna Therapeutics B.V., H1 2015 104

Multiple Sclerosis-Pipeline by Antipodean Pharmaceuticals, Inc., H1 2015 105

Multiple Sclerosis-Pipeline by Antisense Therapeutics Limited, H1 2015 106

Multiple Sclerosis-Pipeline by Antitope Limited, H1 2015 107

Multiple Sclerosis-Pipeline by Aphios Corporation, H1 2015 108

Multiple Sclerosis-Pipeline by Apitope International NV, H1 2015 109

Multiple Sclerosis-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 110

Multiple Sclerosis-Pipeline by Argos Therapeutics, Inc., H1 2015 111

Multiple Sclerosis-Pipeline by Array BioPharma Inc., H1 2015 112

Multiple Sclerosis-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 113

Multiple Sclerosis-Pipeline by Athersys, Inc., H1 2015 114

Multiple Sclerosis-Pipeline by Axxam SpA, H1 2015 115

Multiple Sclerosis-Pipeline by Baliopharm AG, H1 2015 116

Multiple Sclerosis-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 117

Multiple Sclerosis-Pipeline by BIOCAD, H1 2015 118

Multiple Sclerosis-Pipeline by Biocon Limited, H1 2015 119

Multiple Sclerosis-Pipeline by Biogen, Inc., H1 2015 120

Multiple Sclerosis-Pipeline by Biokine Therapeutics Ltd., H1 2015 121

Multiple Sclerosis-Pipeline by Biomar Microbial Technologies, H1 2015 122

Multiple Sclerosis-Pipeline by Bionature E.A. Ltd., H1 2015 123

Multiple Sclerosis-Pipeline by Bioncotech Therapeutics S.L., H1 2015 124

Multiple Sclerosis-Pipeline by Bionomics Limited, H1 2015 125

Multiple Sclerosis-Pipeline by Bionure Farma, S.L., H1 2015 126

Multiple Sclerosis-Pipeline by Biovista Inc., H1 2015 127

Multiple Sclerosis-Pipeline by Bolder Biotechnology, Inc., H1 2015 128

Multiple Sclerosis-Pipeline by BrainStorm Cell Therapeutics Inc., H1 2015 129

Multiple Sclerosis-Pipeline by Caladrius Biosciences, Inc. , H1 2015 130

Multiple Sclerosis-Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 131

Multiple Sclerosis-Pipeline by CASI Pharmaceuticals Inc., H1 2015 132

Multiple Sclerosis-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 133

Multiple Sclerosis-Pipeline by Cell Cure Neurosciences, Ltd., H1 2015 134

Multiple Sclerosis-Pipeline by Cellceutix Corporation, H1 2015 135

Multiple Sclerosis-Pipeline by Cognosci, Inc., H1 2015 136

Multiple Sclerosis-Pipeline by Compugen Ltd., H1 2015 137

Multiple Sclerosis-Pipeline by Creabilis SA, H1 2015 138

Multiple Sclerosis-Pipeline by Critical Outcome Technologies Inc., H1 2015 139

Multiple Sclerosis-Pipeline by Daval International Limited, H1 2015 140

Multiple Sclerosis-Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 141

Multiple Sclerosis-Pipeline by Digna Biotech, S.L., H1 2015 142

Multiple Sclerosis-Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 143

Multiple Sclerosis-Pipeline by Dong-A Socio Group, H1 2015 144

Multiple Sclerosis-Pipeline by Effimune SAS, H1 2015 145

Multiple Sclerosis-Pipeline by Eisai Co., Ltd., H1 2015 146

Multiple Sclerosis-Pipeline by Endece, LLC, H1 2015 147

Multiple Sclerosis-Pipeline by Evgen Limited, H1 2015 148

Multiple Sclerosis-Pipeline by Evotec AG, H1 2015 149

Multiple Sclerosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 150

Multiple Sclerosis-Pipeline by Forward Pharma A/S, H1 2015 151

Multiple Sclerosis-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 152

Multiple Sclerosis-Pipeline by GeNeuro SA, H1 2015 153

Multiple Sclerosis-Pipeline by Genmab A/S, H1 2015 154

Multiple Sclerosis-Pipeline by Genzyme Corporation, H1 2015 155

Multiple Sclerosis-Pipeline by GlaxoSmithKline Plc, H1 2015 156

Multiple Sclerosis-Pipeline by GliaCure Inc., H1 2015 157

Multiple Sclerosis-Pipeline by Glialogix, Inc., H1 2015 158

Multiple Sclerosis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 159

Multiple Sclerosis-Pipeline by Hanwha Chemical Corporation, H1 2015 160

Multiple Sclerosis-Pipeline by Harbor Therapeutics, Inc., H1 2015 161

Multiple Sclerosis-Pipeline by Hutchison MediPharma Limited, H1 2015 162

Multiple Sclerosis-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 163

Multiple Sclerosis-Pipeline by Iltoo Pharma, H1 2015 164

Multiple Sclerosis-Pipeline by Immunaffect B.V., H1 2015 165

Multiple Sclerosis-Pipeline by Immune Response BioPharma, Inc., H1 2015 166

Multiple Sclerosis-Pipeline by ImmuNext, Inc., H1 2015 167

Multiple Sclerosis-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 168

Multiple Sclerosis-Pipeline by InDex Pharmaceuticals AB, H1 2015 169

Multiple Sclerosis-Pipeline by Innate Immunotherapeutics Limited, H1 2015 170

Multiple Sclerosis-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 171

Multiple Sclerosis-Pipeline by InteKrin Therapeutics, Inc., H1 2015 172

Multiple Sclerosis-Pipeline by Invion Limited, H1 2015 173

Multiple Sclerosis-Pipeline by Io Therapeutics, Inc., H1 2015 174

Multiple Sclerosis-Pipeline by Kadimastem Ltd., H1 2015 175

Multiple Sclerosis-Pipeline by Kadmon Corporation, LLC, H1 2015 176

Multiple Sclerosis-Pipeline by KAHR medical Ltd., H1 2015 177

Multiple Sclerosis-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 178

Multiple Sclerosis-Pipeline by Kareus Therapeutics, SA, H1 2015 179

Multiple Sclerosis-Pipeline by Karo Bio AB, H1 2015 180

Multiple Sclerosis-Pipeline by Kineta, Inc., H1 2015 181

Multiple Sclerosis-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 182

Multiple Sclerosis-Pipeline by Lanthio Pharma B.V., H1 2015 183

Multiple Sclerosis-Pipeline by Lead Discovery Center GmbH, H1 2015 184

Multiple Sclerosis-Pipeline by Longevity Biotech, Inc, H1 2015 185

Multiple Sclerosis-Pipeline by MacroGenics, Inc., H1 2015 186

Multiple Sclerosis-Pipeline by MAKScientific, LLC, H1 2015 187

Multiple Sclerosis-Pipeline by Mapi Pharma Ltd., H1 2015 188

Multiple Sclerosis-Pipeline by MedAnnex Ltd, H1 2015 189

Multiple Sclerosis-Pipeline by MedDay, H1 2015 190

Multiple Sclerosis-Pipeline by MedImmune, LLC, H1 2015 191

Multiple Sclerosis-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 192

Multiple Sclerosis-Pipeline by Merck KGaA, H1 2015 193

Multiple Sclerosis-Pipeline by Meta-IQ ApS, H1 2015 194

Multiple Sclerosis-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 195

Multiple Sclerosis-Pipeline by MSM Protein Technologies, Inc., H1 2015 196

Multiple Sclerosis-Pipeline by Neuralstem, Inc., H1 2015 197

Multiple Sclerosis-Pipeline by Neuren Pharmaceuticals Limited, H1 2015 198

Multiple Sclerosis-Pipeline by Neurotec Pharma SL, H1 2015 199

Multiple Sclerosis-Pipeline by Nordic Life Science Pipeline Inc., H1 2015 200

Multiple Sclerosis-Pipeline by Novartis AG, H1 2015 201

Multiple Sclerosis-Pipeline by Nuron Biotech, Inc., H1 2015 202

Multiple Sclerosis-Pipeline by Ocata Therapeutics, Inc., H1 2015 203

Multiple Sclerosis-Pipeline by Octapharma AG, H1 2015 204

Multiple Sclerosis-Pipeline by Omeros Corporation, H1 2015 205

Multiple Sclerosis-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 206

Multiple Sclerosis-Pipeline by Opexa Therapeutics, Inc., H1 2015 207

Multiple Sclerosis-Pipeline by OPKO Health, Inc., H1 2015 208

Multiple Sclerosis-Pipeline by Padlock Therapeutics, Inc., H1 2015 209

Multiple Sclerosis-Pipeline by Peptinov SAS, H1 2015 210

Multiple Sclerosis-Pipeline by Pfenex Inc., H1 2015 211

Multiple Sclerosis-Pipeline by Pfizer Inc., H1 2015 212

Multiple Sclerosis-Pipeline by PharmatrophiX, Inc., H1 2015 213

Multiple Sclerosis-Pipeline by Pieris AG, H1 2015 214

Multiple Sclerosis-Pipeline by Plexxikon Inc., H1 2015 215

Multiple Sclerosis-Pipeline by ProNoxis AB, H1 2015 216

Multiple Sclerosis-Pipeline by Provid Pharmaceuticals, Inc., H1 2015 217

Multiple Sclerosis-Pipeline by Q Therapeutics, Inc., H1 2015 218

Multiple Sclerosis-Pipeline by RAPID Pharmaceuticals AG, H1 2015 219

Multiple Sclerosis-Pipeline by Receptos, Inc., H1 2015 220

Multiple Sclerosis-Pipeline by RedHill Biopharma Ltd., H1 2015 221

Multiple Sclerosis-Pipeline by Regenesance BV, H1 2015 222

Multiple Sclerosis-Pipeline by Resverlogix Corp., H1 2015 223

Multiple Sclerosis-Pipeline by ReveraGen BioPharma, Inc., H1 2015 224

Multiple Sclerosis-Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 225

Multiple Sclerosis-Pipeline by SanBio, Inc., H1 2015 226

Multiple Sclerosis-Pipeline by Sanofi, H1 2015 227

Multiple Sclerosis-Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015 228

Multiple Sclerosis-Pipeline by Sareum Holdings Plc, H1 2015 229

Multiple Sclerosis-Pipeline by Siena Biotech S.p.A., H1 2015 230

Multiple Sclerosis-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 231

Multiple Sclerosis-Pipeline by SOM Innovation Biotech SL, H1 2015 232

Multiple Sclerosis-Pipeline by Sorrento Therapeutics, Inc., H1 2015 233

Multiple Sclerosis-Pipeline by Synthetic Biologics, Inc., H1 2015 234

Multiple Sclerosis-Pipeline by Synthon Holdings BV, H1 2015 235

Multiple Sclerosis-Pipeline by Targazyme, Inc., H1 2015 236

Multiple Sclerosis-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 237

Multiple Sclerosis-Pipeline by Therapix Biosciences Ltd, H1 2015 238

Multiple Sclerosis-Pipeline by TikoMed AB, H1 2015 239

Multiple Sclerosis-Pipeline by Toleranzia AB, H1 2015 240

Multiple Sclerosis-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 241

Multiple Sclerosis-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 242

Multiple Sclerosis-Pipeline by Vaccinex, Inc., H1 2015 243

Multiple Sclerosis-Pipeline by Vakzine Projekt Management GmbH, H1 2015 244

Multiple Sclerosis-Pipeline by Varinel, Inc., H1 2015 245

Multiple Sclerosis-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 246

Multiple Sclerosis-Pipeline by Vicore Pharma AB, H1 2015 247

Multiple Sclerosis-Pipeline by Virogenomics, Inc., H1 2015 248

Multiple Sclerosis-Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 249

Multiple Sclerosis-Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 250

Multiple Sclerosis-Pipeline by Xenetic Biosciences plc, H1 2015 251

Multiple Sclerosis-Pipeline by XenoPort, Inc., H1 2015 252

Multiple Sclerosis-Pipeline by XL-protein GmbH, H1 2015 253

Multiple Sclerosis-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 254

Assessment by Monotherapy Products, H1 2015 255

Assessment by Combination Products, H1 2015 256

Number of Products by Stage and Target, H1 2015 258

Number of Products by Stage and Mechanism of Action, H1 2015 270

Number of Products by Stage and Route of Administration, H1 2015 280

Number of Products by Stage and Molecule Type, H1 2015 282

Multiple Sclerosis Therapeutics-Recent Pipeline Updates, H1 2015 684

Multiple Sclerosis-Dormant Projects, H1 2015 814

Multiple Sclerosis-Dormant Projects (Contd..1), H1 2015 815

Multiple Sclerosis-Dormant Projects (Contd..2), H1 2015 816

Multiple Sclerosis-Dormant Projects (Contd..3), H1 2015 817

Multiple Sclerosis-Dormant Projects (Contd..4), H1 2015 818

Multiple Sclerosis-Dormant Projects (Contd..5), H1 2015 819

Multiple Sclerosis-Dormant Projects (Contd..6), H1 2015 820

Multiple Sclerosis-Dormant Projects (Contd..7), H1 2015 821

Multiple Sclerosis-Dormant Projects (Contd..8), H1 2015 822

Multiple Sclerosis-Dormant Projects (Contd..9), H1 2015 823

Multiple Sclerosis-Dormant Projects (Contd..10), H1 2015 824

Multiple Sclerosis-Dormant Projects (Contd..11), H1 2015 825

Multiple Sclerosis-Dormant Projects (Contd..12), H1 2015 826

Multiple Sclerosis-Dormant Projects (Contd..13), H1 2015 827

Multiple Sclerosis-Dormant Projects (Contd..14), H1 2015 828

Multiple Sclerosis-Dormant Projects (Contd..15), H1 2015 829

Multiple Sclerosis-Dormant Projects (Contd..16), H1 2015 830

Multiple Sclerosis-Dormant Projects (Contd..17), H1 2015 831

Multiple Sclerosis-Discontinued Products, H1 2015 832

Multiple Sclerosis-Discontinued Products (Contd..1), H1 2015 833

Multiple Sclerosis-Discontinued Products (Contd..2), H1 2015 834

Multiple Sclerosis-Discontinued Products (Contd..3), H1 2015 835

Multiple Sclerosis-Discontinued Products (Contd..4), H1 2015 836

List of Figures

Number of Products under Development for Multiple Sclerosis, H1 2015 44

Number of Products under Development for Multiple Sclerosis-Comparative Analysis, H1 2015 45

Number of Products under Development by Companies, H1 2015 46

Number of Products under Investigation by Universities/Institutes, H1 2015 62

Comparative Analysis by Late Stage Development, H1 2015 66

Comparative Analysis by Clinical Stage Development, H1 2015 67

Comparative Analysis by Early Stage Products, H1 2015 68

Assessment by Monotherapy Products, H1 2015 255

Assessment by Combination Products, H1 2015 256

Number of Products by Top 10 Targets, H1 2015 257

Number of Products by Stage and Top 10 Targets, H1 2015 257

Number of Products by Top 10 Mechanism of Actions, H1 2015 269

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 269

Number of Products by Top 10 Routes of Administration, H1 2015 279

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 279

Number of Products by Top 10 Molecule Types, H1 2015 281

Number of Products by Stage and Top 10 Molecule Types, H1 2015 281

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science

AbbVie Inc.

Acadia Pharmaceuticals Inc.

Acorda Therapeutics, Inc.

Actelion Ltd

Addex Therapeutics Ltd

Aegis Therapeutics, LLC

Affectis Pharmaceuticals AG

AiCuris GmbH & Co. KG

Alkermes Plc

Allozyne, Inc.

Amarna Therapeutics B.V.

Antipodean Pharmaceuticals, Inc.

Antisense Therapeutics Limited

Antitope Limited

Aphios Corporation

Apitope International NV

Arena Pharmaceuticals, Inc.

Argos Therapeutics, Inc.

Array BioPharma Inc.

Arrien Pharmaceuticals, LLC

Athersys, Inc.

Axxam SpA

Baliopharm AG

Bio-Cancer Treatment International Limited

BIOCAD

Biocon Limited

Biogen, Inc.

Biokine Therapeutics Ltd.

Biomar Microbial Technologies

Bionature E.A. Ltd.

Bioncotech Therapeutics S.L.

Bionomics Limited

Bionure Farma, S.L.

Biovista Inc.

Bolder Biotechnology, Inc.

BrainStorm Cell Therapeutics Inc.

Caladrius Biosciences, Inc.

CalAsia Pharmaceuticals, Inc.

CASI Pharmaceuticals Inc.

Catalyst Pharmaceutical Partners, Inc.

Cell Cure Neurosciences, Ltd.

Cellceutix Corporation

Cognosci, Inc.

Compugen Ltd.

Creabilis SA

Critical Outcome Technologies Inc.

Daval International Limited

Deltanoid Pharmaceuticals Inc.

Digna Biotech, S.L.

Dimerix Bioscience Pty Ltd

Dong-A Socio Group

Effimune SAS

Eisai Co., Ltd.

Endece, LLC

Evgen Limited

Evotec AG

F. Hoffmann-La Roche Ltd.

Forward Pharma A/S

Genervon Biopharmaceuticals, LLC

GeNeuro SA

Genmab A/S

Genzyme Corporation

GlaxoSmithKline Plc

GliaCure Inc.

Glialogix, Inc.

HanAll Biopharma Co., Ltd.

Hanwha Chemical Corporation

Harbor Therapeutics, Inc.

Hutchison MediPharma Limited

Idera Pharmaceuticals, Inc.

Iltoo Pharma

Immunaffect B.V.

Immune Response BioPharma, Inc.

ImmuNext, Inc.

Inbiopro Solutions Pvt. Ltd.

InDex Pharmaceuticals AB

Innate Immunotherapeutics Limited

Inovio Pharmaceuticals, Inc.

InteKrin Therapeutics, Inc.

Invion Limited

Io Therapeutics, Inc.

Kadimastem Ltd.

Kadmon Corporation, LLC

KAHR medical Ltd.

KaloBios Pharmaceuticals, Inc.

Kareus Therapeutics, SA

Karo Bio AB

Kineta, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lanthio Pharma B.V.

Lead Discovery Center GmbH

Longevity Biotech, Inc

MacroGenics, Inc.

MAKScientific, LLC

Mapi Pharma Ltd.

MedAnnex Ltd

MedDay

MedImmune, LLC

Meiji Seika Pharma Co., Ltd.

Merck KGaA

Meta-IQ ApS

Mitsubishi Tanabe Pharma Corporation

MSM Protein Technologies, Inc.

Neuralstem, Inc.

Neuren Pharmaceuticals Limited

Neurotec Pharma SL

Nordic Life Science Pipeline Inc.

Novartis AG

Nuron Biotech, Inc.

Ocata Therapeutics, Inc.

Octapharma AG

Omeros Corporation

Ono Pharmaceutical Co., Ltd.

Opexa Therapeutics, Inc.

OPKO Health, Inc.

Padlock Therapeutics, Inc.

Peptinov SAS

Pfenex Inc.

Pfizer Inc.

PharmatrophiX, Inc.

Pieris AG

Plexxikon Inc.

ProNoxis AB

Provid Pharmaceuticals, Inc.

Q Therapeutics, Inc.

RAPID Pharmaceuticals AG

Receptos, Inc.

RedHill Biopharma Ltd.

Regenesance BV

Resverlogix Corp.

ReveraGen BioPharma, Inc.

Rigel Pharmaceuticals, Inc.

SanBio, Inc.

Sanofi

Santhera Pharmaceuticals Holding AG

Sareum Holdings Plc

Siena Biotech S.p.A.

SK Biopharmaceuticals Co., Ltd.

SOM Innovation Biotech SL

Sorrento Therapeutics, Inc.

Synthetic Biologics, Inc.

Synthon Holdings BV

Targazyme, Inc.

Teva Pharmaceutical Industries Limited

Therapix Biosciences Ltd

TikoMed AB

Toleranzia AB

Tolero Pharmaceuticals, Inc.

Upsher-Smith Laboratories, Inc.

Vaccinex, Inc.

Vakzine Projekt Management GmbH

Varinel, Inc.

Vertex Pharmaceuticals Incorporated

Vicore Pharma AB

Virogenomics, Inc.

Vitae Pharmaceuticals, Inc.

VivaCell Biotechnology Espana S.L.

Xenetic Biosciences plc

XenoPort, Inc.

XL-protein GmbH

Zydus Cadila Healthcare Limited

Multiple Sclerosis Therapeutic Products under Development, Key Players in Multiple Sclerosis Therapeutics, Multiple Sclerosis Pipeline Overview, Multiple Sclerosis Pipeline, Multiple Sclerosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com